Skip to main content
TrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor about whether a trial is right for you.
RECRUITINGINTERVENTIONAL

Personalised Multicomponent Exercise Programme in Peripheral Arterial Disease

Personalisation of Non-surgical Treatment in Peripheral Arterial Disease Using a Multicomponent Exercise Approach

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.

About This Trial

Peripheral arterial disease (PAD) is characterised as an atherosclerotic disease, most common in the lower limbs (aortoiliac, femoropopliteal, and infrapopliteal arterial segments), which causes a decrease in blood flow to the areas adjacent to and posterior to the affected area. Intermittent claudication (IC) is the most common symptom in this disease that appears with exertion and relieves with rest, causing fatigue, cramps, discomfort, or pain in the lower limbs due to limited blood flow to the affected muscles. Supervised physical exercise has emerged as the first line of intervention in improving the symptoms of intermittent claudication and disease progression, and in the last decade there has been an exponential increase in the use of wearable technologies to monitor dose-response. However, the approach used is still simplistic because it is not personalised. In other words, patients with similar diagnoses and symptoms get the same treatment, without personalising the stimulus according to their exercise responses and level of adaptation. With this in mind, this study aims to monitoring the real-time response of a multicomponent exercise programme (cardiovascular and resistance training) to personalise the dose-response, and use artificial intelligence models to gather and analyse vast amounts of data towards grouping/differentiating based on individual responses. The main hypothesis is that a supervised multicomponent exercise programme will improve the functional capacity of patients with PAD in a cluster personalised approach.

Who May Be Eligible (Plain English)

Who May Qualify: - Diagnosed with clinically stable PAD; - An ankle-brachial index (ABI) between 0.41-0.90 at rest in one or both lower limbs; - Mild to moderate claudication, corresponding to Fontaine Stage IIa and IIb; - A history of ambulatory leg pain; - Ambulatory leg pain confirmed by treadmill test; - Able to provide written consent. Who Should NOT Join This Trial: - Noncompressible, calcified, tibial arteries (resting ABI ≥ 1.4); - Use of medication that could influence claudication (e.g. Cilostazol or Pentoxifylline) 3 months prior to investigation; - Previous intervention (e.g. balloon angioplasty, stenting, bypass, exercise programme); - Inability to walk on a treadmill at a speed of 3.2 km/h (2 mph); - Participation in the past 3 months in a clinical trial or exercise program; - Asymptomatic PAD determined from the medical history; - Exercise limited by factors other diseases or conditions than intermittent claudication; - Angina pectoris, congestive heart failure, chronic obstructive pulmonary disease, severe arthritis, or limb amputation. Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language
Inclusion Criteria: * Diagnosed with clinically stable PAD; * An ankle-brachial index (ABI) between 0.41-0.90 at rest in one or both lower limbs; * Mild to moderate claudication, corresponding to Fontaine Stage IIa and IIb; * A history of ambulatory leg pain; * Ambulatory leg pain confirmed by treadmill test; * Able to provide written consent. Exclusion Criteria: * Noncompressible, calcified, tibial arteries (resting ABI ≥ 1.4); * Use of medication that could influence claudication (e.g. Cilostazol or Pentoxifylline) 3 months prior to investigation; * Previous intervention (e.g. balloon angioplasty, stenting, bypass, exercise programme); * Inability to walk on a treadmill at a speed of 3.2 km/h (2 mph); * Participation in the past 3 months in a clinical trial or exercise program; * Asymptomatic PAD determined from the medical history; * Exercise limited by factors other diseases or conditions than intermittent claudication; * Angina pectoris, congestive heart failure, chronic obstructive pulmonary disease, severe arthritis, or limb amputation.

Treatments Being Tested

BEHAVIORAL

Exercise

Patients randomised to the intervention arm will undergo non-consecutive training sessions three times a week for a period of 12 weeks. The training session is divided into an aerobic and a resistance training component, with a 5-min warm-up (stretching exercises) and a 5-min cool-down (stretching and relaxing exercises). The cardiovascular component will comprise a progressive exercise duration from 30 to 40 minutes, an exercise intensity promoting moderate to severe claudication pain between 8-12 minutes, with rest time until the pain disappears, and a personalised load progression manipulated based on the claudication pain level, reaching a total of 60 minutes of walking per session. The resistance training component will comprise dynamic muscle contraction exercises (Leg extension, unilateral hip extension, and standing calf raise), with a load progression from 50% of 1-estimated one repetition maximum (e-RM) to 80% of 1-eRM.

BEHAVIORAL

Usual care

Patients randomised to the active comparator arm will be advised about the importance of lifestyle modification (including general advice to increase walking but without specific recommendations about the exercise program) for a period of 12 weeks.

Locations (3)

Hospital Centre Hospitalar de Trás-os-Montes e Alto Douro
Vila Real, Portugal
Research Centre in Sports Sciences, Health Sciences and Human Development
Vila Real, Portugal
University of Trás-os-Montes and Alto Douro
Vila Real, Portugal